“There are more reasons to invest in medical cannabis in Portugal than challenges,” says health consultant

Entrepreneurs, regulators and experts on the subject have been meeting in Lisbon, since Wednesday, for the fourth edition of the international conference CannX Lisbon. In an interview with Jornal Económico, one of the speakers at this conference, considers that the boom in this market in Portugal shows no signs of slowing down by international investors.

One year after the entry into force of the legislation that allowed the marketing, in Portuguese pharmacies, of cannabis-based products and substances, there was a tree on the market in Portugal. Currently, there are six companies operating in the market, with only five of them having a license to cultivate the plant.

The emerging growth in Portugal is remarkable and betting on what is called “green gold” should continue to grow according to the trend. And that was precisely what was discussed in the fourth edition of the international conference CannX Lisbon 2020, which took place this Thursday at FIL.

Certain that Portugal could be a key element for the expansion of this market not only in Europe, but also in the world, Luísa Cruz from WiseHs, professor Alexandre Quintanilha and lawyer Carlos Nunes sat down to discuss the opportunities and challenges of investing in Portugal. Speaking in English to an audience of investors, businessmen and consultants, the lawyer stressed that due to the difficulty in obtaining licenses from Infarmed, “a lot of patience” is needed.

“This [opening a medical cannabis business in Portugal] requires a lot of patience because we are always starting and stopping because of Infarmed. But all steps are important. Each step means we are closer to obtaining the necessary licenses ”, he explained.

But waiting is no reason not to invest. In fact, according to the consultant, there are about 10 reasons to make this investment. "There is a favorable position in Portugal in relation to other countries in Europe and this can be seen in the international investment we have seen recently," he explained to Jornal Económico.

In addition to the climate and soil available for growing marijuana, which result in a very low cost price compared to other international markets, and which in turn help to profit the companies' businesses, Portugal has other aspects in its favor.

"We have a very clear and regulated situation here, since Infarmed has a great reputation at European level", explained the expert. "Obviously, with the license granted by this entity there is a very high value at European level and for other markets as well".

Another aspect is, without a doubt, the political stability that led to the approval of the legalization of medicinal cannabis in Parliament with a majority in favor and the favorable geographical position in Europe. For example, companies like Tilray and EXMceuticals they decided to bet, strategically, in Portugal precisely because it will serve as a “gateway” to the European market.

There are also some added facilities for investors, such as gold visas, the quality of life, and the presence of technical and scientific entities dedicated to providing legal support and assisting foreign companies in applying for Infarmed.

“Portuguese and qualified human resources are another great benefit in betting on Portugal,” continued Luísa Cruz, adding that there is a greater desire to embrace the opportunities that may result from this industry. However, this workforce is not specialized yet, for that it is necessary to have more opportunities for specialization that should come from employers and interested workers. "You will have to start from there, since these themes are not disclosed in universities or polytechnics".

What is certain is that we are witnessing a tree of this market in Portugal. “Everyone is interested. It is a business that has a very good profitability and return on investment ”, he stressed.

Read more
Related

Medical cannabis company invested over one million euros in Portugal

Paulo Martins was appointed head of operations for Canadian EXMceuticals, the first company licensed by Infarmed for research and development of cannabis-based pharmaceutical products in Portugal. The CEO tells JE that after the first investment phase in Lisbon, the inauguration of the first industrial unit for the production of pharmaceutical grade cannabinoid ingredients follows.

Cannabis. Portugal receives sixth operation and points Portuguese to CEO

In November 2019, EXMceuticals obtained a license from Infarmed to import, implement Research and Development and refine cannabinoids and cannabis-based ingredients for medicinal purposes in Portugal. Paulo Martins was appointed as CEO of operations in Portugal.

Infarmed has already authorized five companies to grow cannabis for medicinal purposes

Tilray Portugal has a Good Manufacturing Practices certificate, in addition to authorization for cultivation, import and export in the Cantanhede and Reguengos de Monsaraz area. The rest are Terra Verde, in Alcochete, RPK Biopharma, in Sintra and Aljustrel, Sabores Púrpura, in Tavira, and VF 1883 Pharmaceuticals, in Benavente.

First investment fund in Europe dedicated to cannabis is attentive to Portugal

The Medical Cannabis and Wellness ETF fund is now available and will be listed in Germany, and is valid for investors in the United Kingdom, Italy and Ireland. Canadians explain that Canadian cannabis producers, located in Portugal, will not be included in the index due to production for recreational use in other countries.

Canadian giant invests US $ 6 million in Portuguese “green gold”

Holigen invested in a cultivation area in Aljustrel with a capacity to produce 500 tonnes per year. For Flowr, “the acquisition of all of Holigen is the natural evolution of our global cannabis strategy”.

Medical marijuana giant to export 3 million euros in cannabis to Germany

The first order goes to Cannamedical, in Cologne. According to the company, the operation should be carried out in the fall of 2019.
Recommended

Antonoaldo Neves: “TAP will fly again”

With a fleet of 105 airplanes that served more than three thousand flights a week and a universe of around 10 thousand workers, TAP's CEO, Antonoaldo Neves, sent this message to motivate all employees towards the carrier's goal “to fly again "

Sustainable fashion. Five innovative projects that received € 1 million from the H&M Foundation

The Global Change Award winning ideas range from cotton production using biotechnology to the creation of polyester using greenhouse gases.

One year of reduced passes. Passenger increase over 20%

With the support of 120 million euros from the Environmental Fund, many families saw savings of more than 100 euros, since a pass between Setúbal and Lisbon cost 158,75 euros, from Mafra to Lisbon a price of 154 euros, 82,45 euros from Vila Franca de Xira, 80,35 euros from Cascais and 81,85 euros from Sintra.
Comments